7WGD image
Entry Detail
PDB ID:
7WGD
Title:
X-ray structure of thermostabilized Drosophila dopamine transporter with GABA transporter1-like substitutions in the binding site, in substrate-free form.
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2021-12-28
Release Date:
2022-06-29
Method Details:
Experimental Method:
Resolution:
3.20 Å
R-Value Free:
0.28
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Sodium-dependent dopamine transporter
Mutations:(thermostabilizing)V74A, V275A, V311A, L415A, G538L; (GAT1 like) F43Y, D46G, V120L, D121N, S422Q, G425T, S426V, A117S, F325L, V327S, E384S
Chain IDs:A
Chain Length:536
Number of Molecules:1
Biological Source:Drosophila melanogaster
Polymer Type:polypeptide(L)
Description:Antibody fragment (9D5) heavy chain
Chain IDs:C (auth: H)
Chain Length:219
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:Antibody fragment (9D5) Light Chain
Chain IDs:B (auth: L)
Chain Length:214
Number of Molecules:1
Biological Source:Mus musculus
Primary Citation
Structural insights into GABA transport inhibition using an engineered neurotransmitter transporter.
Embo J. 41 e110735 e110735 (2022)
PMID: 35796008 DOI: 10.15252/embj.2022110735

Abstact

γ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter, and its levels in the synaptic space are controlled by the GABA transporter isoforms (GATs). GATs are structurally related to biogenic amine transporters but display interactions with distinct inhibitors used as anti-epileptics. In this study, we engineer the binding pocket of Drosophila melanogaster dopamine transporter to resemble GAT1 and determine high-resolution X-ray structures of the modified transporter in the substrate-free state and in complex with GAT1 inhibitors NO711 and SKF89976a that are analogs of tiagabine, a medication prescribed for the treatment of partial seizures. We observe that the primary binding site undergoes substantial shifts in subsite architecture in the modified transporter to accommodate the two GAT1 inhibitors. We also observe that SKF89976a additionally interacts at an allosteric site in the extracellular vestibule, yielding an occluded conformation. Interchanging SKF89976a interacting residue in the extracellular loop 4 between GAT1 and dDAT suggests a role for this motif in the selective control of neurotransmitter uptake. Our findings, therefore, provide vital insights into the organizational principles dictating GAT1 activity and inhibition.

Legend

Protein

Chemical

Disease

Primary Citation of related structures